PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 2128211
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 2128211
The global glaucoma surgery devices market is experiencing steady growth as the prevalence of glaucoma continues to rise worldwide. Glaucoma is one of the leading causes of irreversible blindness, and surgical intervention becomes necessary when medications and laser therapies fail to adequately control intraocular pressure (IOP). The market includes glaucoma drainage implants, minimally invasive glaucoma surgery (MIGS) devices, laser systems, filtration devices, and various surgical consumables designed to improve patient outcomes while reducing treatment burden.
The global glaucoma surgery devices market size was valued at USD 1.55 billion in 2025 and is projected to increase from USD 1.64 billion in 2026 to USD 2.48 billion by 2034, registering a CAGR of 5.3% during the forecast period. North America dominated the market with a 36.13% share in 2025, supported by advanced healthcare infrastructure, strong reimbursement systems, and rapid adoption of innovative glaucoma treatment technologies.
Market Trends
Growth of Implantable and Advanced Laser-Based Technologies
A major trend shaping the glaucoma surgery devices market is the increasing adoption of implantable glaucoma devices and next-generation laser technologies. Manufacturers are focusing on sustained-release intracameral implants that reduce dependence on daily eye drops and improve long-term treatment adherence.
Additionally, laser-assisted glaucoma surgery is evolving through visualization-guided systems that improve surgical precision and safety. The growing use of advanced imaging technologies and minimally invasive approaches is helping ophthalmologists achieve better clinical outcomes while minimizing patient recovery times.
Market Drivers
Rising Global Burden of Glaucoma
The increasing prevalence of glaucoma is one of the primary factors driving market growth. Aging populations, rising diabetes incidence, and improved disease awareness are leading to higher diagnosis rates worldwide.
As more patients progress to moderate and advanced stages of glaucoma, demand for surgical interventions continues to rise. The growing preference for minimally invasive glaucoma surgery (MIGS) procedures is further accelerating device adoption among healthcare providers and patients.
Market Restraints
High Cost of Surgical Procedures
Despite strong demand, the high cost associated with glaucoma surgeries remains a major restraint. Advanced MIGS procedures require specialized implants, sophisticated surgical tools, and highly trained ophthalmic surgeons.
In addition to procedural expenses, postoperative monitoring, follow-up visits, and potential repeat interventions increase overall treatment costs. These factors can limit patient access, especially in developing economies with lower healthcare spending.
Market Opportunities
Shift Toward Minimally Invasive Glaucoma Surgery (MIGS)
The growing preference for safer and less invasive treatment options is creating significant opportunities within the market. MIGS procedures offer several advantages compared to traditional glaucoma surgeries, including reduced surgical trauma, shorter recovery periods, fewer complications, and improved patient comfort.
As surgeons gain greater experience with MIGS devices and technology continues to improve, manufacturers are expected to introduce innovative products that further expand adoption across both developed and emerging healthcare markets.
Market Challenges
Shortage of Skilled Ophthalmic Surgeons
A key challenge affecting market expansion is the shortage of trained ophthalmologists capable of performing advanced glaucoma procedures. MIGS and other modern surgical techniques require specialized training and expertise.
Many emerging countries continue to face shortages of eye care professionals, limiting access to advanced glaucoma treatments in rural and underserved regions. This workforce gap may slow the adoption of new surgical technologies despite increasing patient demand.
Segment Analysis
By Device Type
The minimally invasive surgery devices segment dominated the market in 2025. The segment's growth is attributed to increasing surgeon preference for MIGS devices due to their superior safety profile, quicker recovery times, and effectiveness in treating mild-to-moderate primary open-angle glaucoma.
Meanwhile, the laser systems segment is projected to expand at a CAGR of 4.7% during the forecast period as advanced laser technologies gain wider clinical acceptance.
By Procedure Type
The minimally invasive surgery segment held the largest market share in 2025 and is expected to account for 39.5% of the market in 2026. MIGS procedures effectively bridge the treatment gap between medication-based therapy and traditional filtration surgeries.
The laser surgery segment is also anticipated to witness steady growth due to improvements in laser-guided treatment platforms.
By End User
The hospitals & ambulatory surgery centers (ASCs) segment dominated the market in 2025 and is projected to hold 66.4% market share in 2026. These facilities possess advanced surgical infrastructure, experienced ophthalmic surgeons, and specialized equipment required for glaucoma interventions.
Specialty eye clinics are expected to witness notable growth due to increasing patient preference for dedicated ophthalmology centers.
Regional Analysis
North America
North America remained the largest regional market, reaching USD 0.56 billion in 2025. The region benefits from strong reimbursement policies, early adoption of innovative technologies, and a high volume of glaucoma procedures.
The U.S. glaucoma surgery devices market is projected to reach approximately USD 0.51 billion in 2026, accounting for around 31.1% of global revenue.
Europe
Europe is expected to grow steadily, reaching USD 0.48 billion by 2026. Growth is supported by strong glaucoma screening programs, advanced healthcare systems, and a large base of ophthalmology specialists across countries such as Germany, the U.K., and France.
Asia Pacific
The Asia Pacific market is projected to reach USD 0.39 billion in 2026. Rising healthcare investments, increasing awareness about glaucoma, and expanding access to ophthalmic services are supporting market expansion across China, Japan, India, and other emerging economies.
Latin America and Middle East & Africa
These regions are expected to experience moderate growth due to improving eye care infrastructure, increasing awareness regarding glaucoma-related blindness, and gradual adoption of advanced surgical technologies.
Competitive Landscape
The glaucoma surgery devices market remains highly competitive, with major companies focusing on innovation, strategic acquisitions, and portfolio expansion. Leading players include:
Recent product launches, FDA approvals, acquisitions, and reimbursement advancements continue to strengthen competition and support innovation across the industry.
Conclusion
The global glaucoma surgery devices market is poised for steady expansion, growing from USD 1.55 billion in 2025 to USD 1.64 billion in 2026, and reaching USD 2.48 billion by 2034. Rising glaucoma prevalence, increasing adoption of minimally invasive glaucoma surgery (MIGS), and continuous technological advancements in implantable and laser-based devices are expected to drive long-term market growth. Although high procedural costs and shortages of trained ophthalmic surgeons remain challenges, ongoing innovation, favorable reimbursement developments, and expanding access to advanced eye care services will continue to support market expansion throughout the forecast period.
Segmentation By Device Type, Procedure Type, End-user, and Region
By Device Type * Glaucoma Drainage Devices
By Procedure Type * Traditional Surgery
By End-user * Hospitals & ASCs
By Region * North America (By Device Type, Procedure Type, End-user, and Country)